John Wingon Ho

US Patent:

6491922, Dec 10, 2002

Filed:

Feb 4, 1997

Appl. No.:

08/794500

Inventors:

John L. Ho - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 39385

US Classification:

4241931, 4242651, 4242691, 514 2

Abstract:

The present invention relates to methods of treating inflammatory diseases, inhibiting production of adhesion molecules on endothelial cells, inhibiting production of nitric oxide synthase by macrophages, inhibiting production of tissue factor by endothelial cells, reversing the inhibitory effects of lipophosphoglycan on endothelial cells or macrophages, and targeting a material to endothelial cells, fibroblasts, or monocytes, by administering lipophosphoglycan or lipophosphoglycan analog. Also disclosed is an isolated DNA molecule suitable for connection to a gene capable of transcription where lipophophoglycan or lipophosphoglycan analogues bind to the DNA molecule and antagonizes transcription of the gene.

US Patent:

6577201, Jun 10, 2003

Filed:

Dec 17, 2001

Appl. No.:

10/023954

Inventors:

John C. Ho - Woodbury NY
Charles Stone - Kings Park NY
Thomas McClelland - Northport NY

Assignee:

Frequency Electronics, Inc. - Northport NY

International Classification:

H03L 706

US Classification:

331 16, 331 25, 331 66, 327156, 375376

Abstract:

A precision oven-controlled crystal oscillator (OCXO) uses an adjustment feedback signal that, when mixed with a reference signal from a stable reference oscillator, accurately controls the generation of an output signal from a voltage controlled crystal oscillator (VCXO). An OCXO according to the invention has high stability and high accuracy. The digital OXCO can be manufactured at low cost, and is particularly beneficial for Code Division Multiple Access (CDMA) base station applications in cellular communication networks an the like.

US Patent:

6753737, Jun 22, 2004

Filed:

Mar 17, 2003

Appl. No.:

10/390557

Inventors:

John C. Ho - Woodbury NY
Charles Stone - Kings Park NY
Thomas McClelland - Northport NY

Assignee:

Frequency Electronics, Inc. - Mitchel Field NY

International Classification:

H03L 706

US Classification:

331 16, 331 25, 331 66, 327156, 375376

Abstract:

A precision oven-controlled crystal oscillator (OCXO) uses an adjustment feedback signal that, when mixed with a reference signal from a stable reference oscillator, accurately controls the generation of an output signal from a voltage controlled crystal oscillator (VCXO). An OCXO according to the invention has high stability and high accuracy. The digital OXCO can be manufactured at low cost, and is particularly beneficial for Code Division Multiple Access (CDMA) base station applications in cellular communication networks an the like.

US Patent:

20030199012, Oct 23, 2003

Filed:

Jan 31, 2003

Appl. No.:

10/357043

Inventors:

John Ho - New York NY, US

International Classification:

A61K039/40
G01N033/554
G01N033/569
C07H021/04
C12P021/02
C12N001/21
C07K014/35
C07K016/12

US Classification:

435/007320, 424/168100, 435/069300, 435/252300, 435/320100, 530/350000, 536/023700, 530/388400

Abstract:

The present invention relates to a nucleic acid construct having a nucleic acid molecule that encodes a factor suppressing an immune response to in a host subject; an isolated antibody against the protein or polypeptide encoded by the nucleic acid molecule; and uses for the protein and its antibody, including in a method for detection of in a sample of tissue or body fluids; a method of vaccinating a mammal against infection by ; a vaccine for preventing infection and disease of mammals by and for actively immunizing mammals against ; and methods of treating inflammatory disease in mammals.

US Patent:

20050267025, Dec 1, 2005

Filed:

Mar 18, 2005

Appl. No.:

11/083624

Inventors:

John Ho - New York NY, US

International Classification:

A61K038/17

US Classification:

514012000

Abstract:

The present invention relates to a vaccine for preventing infection that contains a polypeptide isolated from that suppresses the immune response and induces IL-10 in a subject infected with , and to methods of treating an inflammatory condition in a mammal, vaccinating a mammal against infection by , and treating a mammal for infection by , which involve providing a nucleic acid molecule encoding the polypeptide isolated from that suppresses the immune response and induces IL-10 in a subject infected with , or the polypeptide itself, and administering the nucleic acid molecule or its encoded polypeptide to a mammal.

US Patent:

58637281, Jan 26, 1999

Filed:

Jul 5, 1996

Appl. No.:

8/675921

Inventors:

John Siu-Cheong Ho - East Lansing MI
John T. Loh - Knoxville TN
Melvin S. Schindler - Okemos MI
John L. Wang - East Lansing MI

Assignee:

Board of Trustees operating Michigan State University - East Lansing MI

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

A DNA fragment encoding a carbohydrate binding lectin BJ38 in chromosomal DNA of Bradyrhizobium japonicum is described. The DNA is used as a source of the lectin, as a probe and as DNA for recombinant strains of rhizobium with enhanced nodulation and production in legumes.

US Patent:

56679645, Sep 16, 1997

Filed:

Oct 28, 1994

Appl. No.:

8/331218

Inventors:

John Lap Ho - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12Q 170
C12Q 100

US Classification:

435 5

Abstract:

The ability to monitor the progression of human immunodeficiency virus (HIV) infection in patients is paramount to the study of HIV transmission, in predicting the onset and advancement of disease, and evaluating the clinical efficacy of therapeutics. Present methods available to the clinician for the study of HIV pathogenesis employ surrogate markers. Surrogate markers are biological indicators that tend to reflect, to varying extent, the gradual progression of the asymptomatic state to the development of acquired immune deficiency syndrome (AIDS). The most commonly used markers are CD4. sup. + lymphocyte counts and HIV p24 antigen production. The use of markers to evaluate disease progression suffers from a number of limitations. No known marker consistently reflects disease progression in all patients and stages of disease. Moreover, an effective marker must rapidly reflect the changes associated with antiviral therapy.